GlassScriptPhysician profile
Amy W Gemperli
NPI 1336181718
$3,439.16
in general payments reported to CMS, 2019-2025
19 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $362 · 2021: $372 · 2022: $409 · 2023: $297 · 2024: $770 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,117.06 | 2022-2025 | Clareon, Hydrus Microstent, Rocklatan |
| Abbvie INC. | $650.90 | 2023-2025 | |
| Allergan, INC. | $615.73 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $346.32 | 2019-2021 | |
| Rxsight INC | $100.73 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.32 | 2020-2021 | |
| Sight Sciences, INC. | $93.85 | 2020 | |
| Bausch & Lomb Americas INC. | $89.56 | 2022-2025 | Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $64.82 | 2019-2021 | |
| The Cameron-Ehlen Group, INC. | $62.30 | 2019 | |
| Sun Pharmaceutical Industries INC. | $49.58 | 2019 | |
| Iridex Corporation | $26.41 | 2019 | |
| Thea Pharma INC. | $24.37 | 2023 | |
| Carl Zeiss Meditec, INC. | $21.08 | 2019 | |
| Akorn, INC. | $19.29 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $19.05 | 2024 | Acthar |
| Optos, INC. | $16.46 | 2019 | |
| Glaukos Corporation | $13.80 | 2021 | |
| Genentech USA, INC. | $13.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Gemperli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.